Rx (Prescription Medicine)
USD $ 210.00
Hervycta 440mg 注射液是一种靶向疗法，用于治疗某些类型的癌症。其活性成分是 Trastuzumab，这是一种单克隆抗体，可特异性结合 HER2 蛋白。在某些癌症中，尤其是乳腺癌和胃癌，HER2 蛋白会过度表达，导致癌细胞失控生长。Hervycta 通过与癌细胞表面的 HER2 受体结合，阻断其生长信号，并将癌细胞标记以供体内免疫系统破坏。它还能阻止 HER2 阳性癌细胞的分裂和增殖。
Hervycta 适用于治疗 HER2 阳性乳腺癌（包括早期和转移性）以及 HER2 阳性转移性胃癌或胃食管交界部腺癌。Hervycta 的剂量和给药方式由医疗专业人员根据患者的病情和治疗反应决定。通常通过静脉给予。
常见不良反应可能包括发热、寒战、恶心、呕吐、腹泻、头痛和疲劳。更严重的不良反应可能包括心脏问题（如心功能下降）、肺部问题以及严重的过敏反应。患者应在开始治疗前告知医生任何既往病史，尤其是心脏疾病。Hervycta 应储存在冰箱温度（2°C 至 8°C）下，并避光保存。禁止冷冻。
| Strength | |
|---|---|
| Pack Quantity | |
| Medicine Form | |
| Medicine Type | |
| Rx Status | |
| Molecule | |
| Brand Name | |
| Country Of Origin | |
| Packaging Type |
其他品牌的 Trastuzumab 440 mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
